Track topics on Twitter Track topics that are important to you
Reistone, a one-year-old Shanghai-Beijing-Boston biopharma, has dosed the first patient in global Phase II trial of its JAK1 inhibitor in patients with Ulcerative Colitis and Crohn's disease. The JAK1 candidate was developed by Jiangsu Hengrui. In early 2018, Hengrui established Reistone, complete with financial backing, as a company capable of conducting global trials of China-discovered drugs, Hengrui's own and those of other companies. The JAK1 clinical trial is a randomized, double-blind, placebo-controlled, four-armed, multi-center Phase II test with safety and efficacy endpoints. More details....
Stock Symbol: (SHA: 600276)
Share this with colleagues:
Original Article: Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBDNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...